Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy

  • Technology appraisal guidance
  • TA307
  • Published: 
Download guidance (PDF)

6 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the CRD and CHE Technology Assessment Group, University of York:

  • Wade R, Duarte A et al. Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, April 2013

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, Professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Sanofi

Professional or specialist and patient or carer groups:

  • Beating Bowel Cancer

  • Cancer Research UK

  • Royal College of Nursing

Other consultees:

  • Department of Health

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Pfizer

  • Roche

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on aflibercept by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Richard Adams, Senior Lecturer and Consultant Oncologist, Velindre Cancer Centre and Cardiff University, nominated by Sanofi - clinical specialist

  • Jacqueline Fraser, nominated by Beating Bowel Cancer - patient expert

  • Helen Minnery, nominated by Beating Bowel Cancer - patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Sanofi

ISBN 978-1-4731-0519-5